What is CranioSense?
CranioSense operates at the intersection of advanced sensor technology and emergency medicine. The company has engineered IPASS, a sophisticated non-invasive diagnostic tool that provides rapid, accurate measurements of intracranial pressure. By replacing traditional, high-risk invasive monitoring procedures with a streamlined patch-and-sensor system, CranioSense is effectively setting a new standard for patient safety. Their market position is defined by a commitment to reducing the morbidity associated with elevated cranial pressure, serving a critical need for both hospital-based neuro-specialists and pre-hospital emergency responders who require immediate, actionable data in life-critical scenarios.
How much funding has CranioSense raised?
CranioSense has raised a total of $5.5M across 1 funding round:
Grant
$5.5M
Grant (2025): $5.5M, investors not publicly disclosed
Key Investors in CranioSense
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for CranioSense?
With this major enterprise-level funding, CranioSense is poised to transition from clinical validation to broad-scale commercialization. The strategic roadmap involves scaling manufacturing capabilities for the IPASS system and expanding clinical trials to secure further regulatory clearances across international markets. By leveraging this capital, the firm intends to integrate its diagnostic technology into standard emergency response protocols, thereby enhancing the quality of care for patients suffering from traumatic brain injuries. Future growth will likely focus on deepening partnerships with major healthcare systems and trauma centers, ensuring that their non-invasive monitoring solution becomes a ubiquitous tool in the global neuro-critical care landscape.
See full CranioSense company page
